HONG KONG, May 6 /Xinhua-PRNewswire-FirstCall/ -- Golden Meditech Company Limited (HKEx: 8180) ('Golden Meditech' or the 'Company') is pleased to announce today that it has obtained the final approval from State Food and Drugs Administration (SFDA) for its new blood treatment device -- Model 3000H Plasma Exchange System and expects to launch the product in the marketplace soon.
(Photo: http://www.xprn.com/xprn/sa/200805061829.jpg )
Mr. KAM Yuen, Chairman of Golden Meditech, said that the Model 3000H is aimed at treating patients suffering blood intoxication, immunological disorders, plasma cell dyscrasias and other diseases caused by poisonous substances. He said that the device and its components and subsystems have all been granted the 'Medical Device Registration Certificate of the People's Republic of China', and the registration is mandatory for all new medical devices before being sold in China market.
He further explained that plasma exchange (PE) or plasmapheresis refers to a process of removing plasma from blood cells and other components by a cell separator through continuous centrifugation. The cells are returned to patients undergoing treatment, while the plasma, which contains antibodies and intoxicants, is discarded and replaced with substitute fluids.
The Model 3000H device can rapidly reduce the toxicants and other harmful components from the patient's blood and restitute deficient essential substances, and this will help them to recover more quickly, he noted.
Mr. KAM emphasized that Golden Meditech, being a high-tech healthcare company specialized in research of blood salvaging, purification, treatment and storage, has established dominant positions in China market and one of its flagship product, the Autologous Blood Recovery System (ABRS) has been installed in most of the large and medium-sized hospitals nationwide.
He said that the Model 3000H, which targets at emergency rooms of those large and medium-sized hospitals, will benefit from the cross-selling opportunities to the Company's exciting customer base. This will help the Model 3000H penetrate the market more quickly, he added.
Golden Meditech:
Founded in 2000 and listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited in December 2001, Golden Meditech is the first hi-tech medical device enterprise that went public outside of the PRC. During the past few years, thanks to its great efforts in innovation and market expansion, as well as its first-mover abilities in capturing the emerging market opportunities, Golden Meditech's medical device, cord blood banking services and Chinese herbal medicine have all established dominant positions in each of its own sectors. Going forward, Golden Meditech will continue its pursuit of becoming China's leading integrated medical group through organic growth, acquisition and strategic investment.
For enquiries, please contact the investor relations department of Golden Meditech Company Limited.
Dennis Haikuan Lu
Telephone: +852-3605-8138
Facsimile: +852-3605-8181
Email:
